Yectames

Quick links to important sections

Yectames

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yectames

Quick Facts: Yectames

Property Description
Active Ingredients Algestone Acetophenide, Estradiol
Form Injectable solution (oil-based)
Pharmacological Class Hormonal Contraceptive Agent, Progestin-Estrogen Combination
Common Use Prevention of pregnancy (contraception)
Origin Synthetic (progestin component) and Derived (estrogen component)

Yectames: Classification and Pharmaceutical Form

Yectames is a specialized Combined Injectable Contraceptive (CIBC), which is a long-acting hormonal medication used for birth control. It belongs to the pharmacological class of Hormonal Contraceptive Agents, utilizing a Progestin-Estrogen Combination. The drug is delivered as an injectable solution via intramuscular injection, a method recognized for achieving sustained hormonal levels over a four-week cycle.

This formulation is designed specifically for women and differentiates itself by eliminating the need for daily medication management typical of oral contraceptives. The combined hormonal approach, established through pharmacological studies, is highly effective in maintaining a continuous state of protection against conception. The formulation, frequently marketed alongside similar products like Perlutal and Anafertin in regions such as Latin America, is positioned as a convenient, once-monthly option.

What is Yectames Made Of? Composition and Origin

The formulation contains two core active ingredients: the progestogen Algestone Acetophenide and the estrogen Estradiol (typically as Estradiol Enantate). These compounds are dissolved in an oil solution that serves as the base/vehicle.

The progestin, Algestone Acetophenide (or Dihydroxyprogesterone Acetophenide), is a synthetic pregnane steroid that provides the powerful progestogenic effect. The chemical design of this combination ensures that both hormonal pathways are targeted simultaneously for maximal contraceptive reliability.

Primary Purpose: Why is Yectames Used?

The single primary purpose of Yectames is achieving contraception, offering an effective and reliable method for the prevention of pregnancy. This utility is a direct result of the medication’s fundamental action, which establishes a continuous state of protection against conception. The combined hormonal activity offers a predictable, non-surgical option for birth control that eliminates the necessity of daily medication compliance.

What side effects are possible with Yectames?

Possible Side Effects and Safety Information

The safety profile of Yectames (Algestone Acetophenide/Estradiol) is characterized by a range of officially documented adverse reactions classified by frequency and affected body system. This combined injectable contraceptive is associated with common, expected hormonal effects, alongside rare but clinically significant risks, as defined by regulatory authorities.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common Headache, nausea, breast tenderness, weight gain, irregular vaginal bleeding or spotting, injection site reactions.
Uncommon/Less Common Migraine, dizziness, abdominal pain, depressed mood, acne, and rash.
Rare Arterial and Venous Thromboembolic Events (VTE/ATE), severe hypertension, and hepatic adenomas.

Serious Safety Considerations

The official labeling documents rare but serious adverse reactions, including the risk of thromboembolism (blood clots, such as Deep Vein Thrombosis or Pulmonary Embolism) and certain neoplasias, including liver tumors. These serious events relate to the Vascular Disorders and Hepatobiliary Disorders system-organ classes.

Time-Related Patterns and Restrictions

Regulatory information notes that menstrual irregularities like spotting are often more frequent during the initial months of treatment, typically decreasing over time. Safety restrictions dictate that the medicine should not be used in individuals with pre-existing conditions such as severe liver impairment, a history of thromboembolic disease, or known hormone-dependent malignancies.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Yectames (Algestone Acetophenide and Estradiol) define its acute overdose profile as being associated with low acute toxicity. Serious or life-threatening adverse effects have generally not been reported following acute overexposure to this combination of hormonal contraceptives, according to prescribing information.

The clinically documented overdose manifestations are typically an extension of the known hormonal effects and are considered non-serious. These may include:

Manifestation Type Documented Signs
Gastrointestinal Nausea and Vomiting
Hormonal Withdrawal bleeding or Vaginal bleeding

Emergency Actions and Management

Regulatory authorities mandate that any suspected overdose requires immediate medical attention. Patients must contact emergency services or a doctor without delay for assessment and continuous monitoring. This action is strictly required despite the low acute toxicity assessment defined in official documentation.

The treatment of a Yectames overdose is symptomatic and supportive. Official labeling confirms that no specific antidote is known for this combined formulation. In the specific context of accidental ingestion by young children, medical assessment is required; although no serious adverse effects are reported, vaginal bleeding may be observed as the primary sign.

Therapeutic Uses of Yectames

Quick Facts: Yectames

  • Primary Therapeutic Domain: Prevention of pregnancy
  • Key Use: Contraception

Yectames is a medication primarily prescribed to help prevent pregnancy. It is utilized as a form of combined injectable contraception for women.

The medication contains a combination of two hormonal compounds: an estrogen, which is estradiol enantate, and a progestogen, which is algestone acetophenide (also known as dihydroxyprogesterone acetophenide, or DHPA). This combination works to support the absence of ovulation as part of its contraceptive effect.

Combined injectable contraceptives like Yectames are administered monthly to support family planning efforts. This type of formulation is one of several available options for women seeking to manage their reproductive health and achieve reliable contraception.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Yectames — Official Regulatory Information

Yectames is a combined hormonal contraceptive and its official use is restricted to women of reproductive age seeking pregnancy prevention. Regulatory bodies mandate that use is strictly contraindicated in populations with specific health risks.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Established for women of reproductive age.
Populations for whom use is contraindicated Females over 35 years old who smoke cigarettes.
Females with a history of thromboembolic disorders (blood clots) or other high vascular risk.
Females with known or suspected breast cancer or other hormone-sensitive malignancy.
Females with significant liver disease, liver tumors, or severe (decompensated) cirrhosis.
Age-related eligibility rules Use is established in adolescents post-menarche; use in older adults is generally not indicated.
Pregnancy and lactation eligibility status Pregnancy is an absolute contraindication; use is not recommended for nursing mothers (lactation).
Eligibility-related restrictions Must be stopped at least 4 weeks before and through 2 weeks after major surgery (due to thrombosis risk).

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in females with a current or past history of thromboembolic disorders or high arterial/venous disease risk.
  • Use is prohibited in females with hormone-sensitive cancers or severe hepatic impairment.
  • The medication is not recommended for use by nursing mothers or by females over 35 who smoke.

Connection to the overall eligibility profile: Government regulatory documents define who can and cannot use this drug by establishing a clear framework of absolute prohibitions related to cardiovascular risk, cancer sensitivity, and severe liver dysfunction. The official labeling permits use only for women of reproductive age who do not present any of these specified prohibitive conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Yectames (Algestone Acetophenide/Estradiol) is primarily governed by pharmacokinetic interactions that can alter the systemic exposure of the active hormonal components. These interactions are a critical regulatory concern for all combined hormonal contraceptives.

Official Interaction Classifications

Interaction Type Description and Official Restriction
Efficacy-Reducing Interactions Co-administration with potent hepatic enzyme inducers (primarily CYP3A4 inducers) is formally contraindicated due to the risk of significantly increasing the clearance of the hormones, potentially compromising contraceptive effectiveness.
Exposure-Increasing Interactions Co-use with strong CYP3A4 inhibitors may increase the plasma concentrations of the hormonal steroids, potentially elevating the risk of adverse effects.
Pharmacodynamic Interactions The established risk of thromboembolic events associated with the estrogen component may be potentiated by co-administration with other agents that affect coagulation factors.

Specific Interacting Substances

Specific interacting medicines that can cause a clinically significant reduction in hormonal exposure include anti-epileptic drugs like Carbamazepine and Phenytoin, the anti-tuberculosis medicine Rifampicin, and certain HIV/HCV protease inhibitors. The herbal product St. John's Wort (Hypericum perforatum) is also officially documented as a potent enzyme inducer that may compromise efficacy. No formal administration-timing rules requiring separation of doses are documented for this injectable formulation. This profile structure is based on the standardized regulatory requirements established by government health authorities for this therapeutic class.

Mechanism of Action

Central Mechanism: Suppression of the HPO Axis

The primary action of Yectames involves high-affinity agonism at Progesterone and Estrogen Receptors in the hypothalamus and pituitary gland. This receptor activation initiates a robust negative feedback loop that halts the secretion of Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH). This primary central cascade leads to the physiological effect of anovulation (the cessation of egg release).


Peripheral Action: Barrier and Lining Modification

The progestin component, Algestone Acetophenide, acts on peripheral targets, inducing a secondary complementary mechanism. It causes the glands of the cervix to secrete thick, viscous mucus, creating a biological barrier that impedes sperm movement. Concurrently, the hormonal activity alters the structure of the uterine lining (endometrium), rendering the tissue non-receptive to implantation.


Mechanistic Synergy and Concentration Dependence

Yectames employs mechanistic synergy where the estrogen component enhances the central inhibitory signal initiated by the progestin. This interaction contributes to enhanced suppression of follicular development. The continuous receptor saturation required for this effect makes the mechanism concentration-dependent and subject to constraints if drug levels fall below the critical threshold due to metabolic acceleration.

Dosage and Administration Information

How to use Yectames

Yectames is administered as a fixed-dose injectable solution and follows a standardized, non-titrated schedule used for combined hormonal contraceptives. The standardized use protocol is precisely defined to ensure continuous administration.


Administration Scope

Instruction Detail
Route of administration Intramuscular (IM) Injection only, delivered deeply into muscle tissue.
Dosing schedule Administration of the full, fixed combination dose (e.g., 75 mg Algestone Acetophenide / 5 mg Estradiol Enantate) without variation.
Age-group administration rules The standard regimen is defined for adult women requiring contraception.
Special procedural conditions The first injection is typically given between Day 1 and Day 5 of a normal menstrual cycle.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Parenteral (Intramuscular Injection)
Frequency pattern Monthly (Once every 30 ± 3 days)
Use-context constraints Continuous Use: The regimen requires a cyclic sequence of monthly injections for the entire period contraception is needed.

Resulting Procedural Structure

Step sequence:

  • Initiation: Administer the first fixed-dose injection via the IM route on the required cycle day.
  • Maintenance: Administer subsequent fixed-dose injections via IM route every 30 ± 3 days, strictly following the interval.
  • Missed Dose: If the injection is significantly delayed, pregnancy must be excluded before the next dose is administered.

Connection to the Overall Use Protocol

The established instructions provide a rigid, standardized procedure where the deep intramuscular injection facilitates the slow, sustained release of the hormonal agents from the oil-based vehicle. This continuous, fixed-interval schedule is a procedural component that governs the consistent maintenance of the hormonal agents in the body.

Recent Clinical Evidence

Yectames: Recent Clinical Evidence


Evidence for Use in Contraception

Research into Yectames, a combined injectable contraceptive that uses Algestone Acetophenide and Estradiol, was conducted through randomized controlled trials (RCTs) and large, prospective clinical studies. These studies were applied in research contexts involving women of reproductive age who were seeking birth control options. Researchers primarily focused on outcomes related to the prevention of pregnancy. These trials were designed to examine the incidence of unintended pregnancy over the monthly injection period.

Studies reported measurements of the incidence of unintended pregnancy within the observed populations. Research uses the Pearl Index—a measurement tracked by studies—to define and report the measurements observed in clinical settings, helping to reflect the group pattern observed during the research period.

Pharmacodynamic and Follow-up Studies

Beyond the primary outcome, specialized clinical pharmacology studies examined the internal effects on the body. Research explored outcomes related to systemic imbalance, monitoring the relationship between the two hormonal components and resulting hormonal changes. Trials also monitored menstrual bleeding patterns, reporting that changes such as spotting, irregular bleeding, or temporary absence of bleeding (amenorrhea) were observed in some study populations.

Long-term research explored the use of Yectames over defined time intervals, with typical efficacy trials including follow-up durations that were limited to approximately one year. Studies monitored the restoration of the menstrual cycle after participants discontinued the medication, describing the time intervals observed for the return to ovulatory function.

What Research Gaps and Uncertainties Remain

Evidence is limited regarding the results of large-scale, current clinical trials that directly compare this specific formulation against newer hormonal contraceptive agents. Subgroup findings are uncertain for certain populations, as the core clinical trials focused on women of reproductive age without major comorbidities. Furthermore, structured, long-term effects are not fully established through prospective studies that exceed follow-up durations of one to two years.

Frequently Asked Questions (FAQ)

Common questions about Yectames (FAQ)


Q: What are the most common mild side effects of Yectames that people talk about?

Regulatory documents state that common adverse reactions include headache, nausea, breast tenderness, weight gain, irregular vaginal bleeding or spotting, and reactions at the injection site. The official information notes that irregular bleeding or spotting is often more frequent during the initial months of treatment but is often observed to decrease over time.


Q: Does taking Yectames make you feel tired or drowsy?

The official safety profile lists dizziness and depressed mood as uncommon adverse reactions. The specific terms 'tiredness' or 'drowsiness' are not explicitly noted in the documented side effect profile for Yectames.


Q: Can Yectames affect my mood or mental clarity?

Depressed mood is officially listed as an uncommon adverse reaction according to the official product information. The regulatory documents do not contain explicit information about changes in mental clarity.


Q: Is it common to have headaches when first starting Yectames?

Headache is officially classified as a common adverse reaction. Regulatory information indicates that certain hormonal side effects, such as menstrual irregularities, are frequently observed during the initial months of use.


Q: Does Yectames cause weight gain or weight loss?

Weight gain is officially listed as a common adverse reaction in the regulatory documents for Yectames. Weight loss, however, is not explicitly documented in the product's official side effect profile.


Q: What should I know about taking Yectames if I have liver disease?

Official regulatory documents define use as strictly contraindicated, or prohibited, in individuals with significant liver disease, liver tumors, or severe (decompensated) cirrhosis. The official documents do not explicitly define use limitations for mild or non-severe liver conditions.


Q: Does Yectames need to be stored in the refrigerator?

No, Yectames must be stored at a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The official labeling specifies that the product should not be frozen or exposed to temperatures outside of this range.


Q: How quickly does Yectames usually start working?

The formulation is designed for deep intramuscular injection, which facilitates the slow and sustained release of the hormonal agents into the body. This continuous process is intended to maintain hormonal levels consistent with its contraceptive effect over the entire monthly cycle.


Q: Does Yectames work the same way as Drug X (a similar drug)?

Yectames is officially classified as a Combined Injectable Contraceptive (CIBC) that works by suppressing the HPO axis (the body’s central hormone regulator) and modifying the uterine lining. This approach is consistent with the established mechanism for this class of combined hormonal contraceptives.


Q: What is the key difference between Yectames and other medicines for the same condition?

The official classification emphasizes that Yectames is a Combined Injectable Contraceptive (CIBC). This means it is administered as a fixed-dose intramuscular injection on a once-monthly schedule, differentiating it from daily oral hormonal methods.


Q: What happens if I stop taking Yectames suddenly?

Research evidence includes studies that monitored the time intervals observed for the restoration of the menstrual cycle and the return to ovulatory function after participants discontinued the medication.


Q: What should I do if I miss a dose of Yectames?

Regulatory guidance specifies that an assessment to exclude pregnancy is required before the next dose is administered, if the monthly injection is significantly delayed. This highlights the critical timing of the standardized monthly schedule.


Q: Does Yectames show up on standard drug tests?

Yectames contains synthetic hormones and is classified as a hormonal contraceptive agent. Standard drug tests are designed to screen for controlled substances, and Yectames does not fall into this category.


Q: Is Yectames a controlled substance?

No, Yectames is officially classified as a hormonal contraceptive agent and is not designated as a controlled substance under regulatory frameworks.


Q: What kind of research has been done on Yectames's effectiveness?

Research evidence for Yectames is based on various study types, including randomized controlled trials (RCTs), large prospective clinical studies, and specialized clinical pharmacology studies.


Q: How strong is the evidence that Yectames actually helps the condition it is approved for?

Efficacy research focuses on the prevention of pregnancy. Efficacy measurements observed in clinical settings are officially reported using the Pearl Index, which is a standardized method for defining the incidence of unintended pregnancy.


Q: Is it normal to feel a bit nauseous the first week on Yectames?

Nausea is officially listed as a common adverse reaction. Regulatory information generally notes that many hormonal side effects are often more frequently observed during the initial months of treatment.


Q: Why do official sites talk about a 'risk evaluation and mitigation strategy' (REMS) for Yectames?

Official safety documents outline rare but serious adverse reactions, including the risk of blood clots (thromboembolic events). Risk Evaluation and Mitigation Strategies (REMS) are plans designed by regulatory bodies to help manage a drug's known or potential serious risks.


Q: What is the typical time frame to see the full effect of Yectames?

The official use protocol is based on a rigid, standardized, fixed-interval monthly schedule. This regimen is designed to facilitate the slow, sustained release of hormones to maintain its intended continuous contraceptive effect throughout the period of use.


Q: If I am already on a medicine for X condition, can Yectames still be used?

Official regulatory documents formally prohibit (contraindicate) co-administration with potent hepatic enzyme inducers, such as certain anti-epileptic drugs and the herbal product St. John's Wort. This prohibition is due to the risk of reducing the hormones' effectiveness.


Q: Is the effect of Yectames permanent, or does it only work while you are taking it?

Research evidence includes monitoring the time intervals observed for the restoration of the menstrual cycle and the return to ovulatory function after participants discontinued the medication. This indicates the effect is not permanent.


Q: Why is Yectames sometimes prescribed for a short period only?

A specific regulatory restriction dictates that the medication must be stopped for a total of at least six weeks surrounding any major surgery. This temporary discontinuation is mandated in regulatory labeling to help mitigate the risk of thrombosis.


Q: Do I need special monitoring tests (like bloodwork) while taking Yectames?

While the regulatory labeling dictates contraindications related to severe liver impairment and high vascular risk, the provided use protocol does not explicitly state that routine monitoring tests are a required procedural component.


Q: Can Yectames affect my ability to drive or operate machinery?

The official safety profile documents potential uncommon adverse reactions, including dizziness and depressed mood. These types of effects may impact physical and mental functioning, which is relevant to activities like driving or operating machinery.


Q: How does Yectames relate to other treatments I've tried?

Yectames is officially classified as a Combined Injectable Contraceptive (CIBC). This classification places it within the larger category of hormonal birth control options that use both a progestin and an estrogen component.

How should Yectames be stored and disposed of?

Storage and Handling Requirements

Official regulatory labeling dictates specific conditions for storing Yectames to ensure its quality and stability. The product must be stored at a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and must be protected from both light and moisture. This is achieved by keeping the medicine in its original container or outer carton, and the container should be tightly closed when not in use.

It is strictly required that the product not be frozen or exposed to temperatures exceeding the specified maximum. If the product is reconstituted or diluted, the label defines a limited in-use stability period (e.g., must be used within 24 hours), after which any unused portion must be immediately discarded.

Disposal Instructions

Official guidance requires that Yectames be disposed of properly to prevent environmental contamination and misuse. Unused, unwanted, or expired medicine should be returned to an authorized drug take-back program or a community collection point. It must not be disposed of in wastewater (flushed down the toilet or poured down a sink). All products, packaging, and handling materials must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yectames found in:

A-Z Index: